Dr. Jeremy B. Desai, CEO & President of Apotex, the Canadian international generics powerhouse, discusses his mandate in 2014 to take the company global, the challenges and opportunities of increasing convergence between the generics, branded and biosimilars sectors globally, and the main growth engines for Apotex looking forward.
Jeremy, you were no stranger to Apotex when you assumed position as President and CEO in August 2014. What was your mandate then and where is the organization today?
"In the past three years, my team and I have developed and implemented a lot of processes, structure and governance in order to maximize the impact of our global footprint"
